Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

Several studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent...

Full description

Bibliographic Details
Main Authors:	Gouvas Nikolaos, Kalambaliki Telenia, Voutsina Alexandra, Saridaki Zenia, Tzardi Maria, Kalykaki Aristea, Sfakianaki Maria, Athanasiadis Athanasios, Xynos Evaghelos, Boukovinas Ioannis, Souglakos John
Format:	Article
Language:	English
Published:	Sciendo 2019-07-01
Series:	Forum of Clinical Oncology
Subjects:	kras-nras mutation colorectal cancer metastatic disease
Online Access:	https://doi.org/10.2478/fco-2018-0005

id	doaj-bd9b256a7b0e4313a8fa70133728181b
record_format	Article
spelling	doaj-bd9b256a7b0e4313a8fa70133728181b2021-09-05T21:00:54ZengSciendoForum of Clinical Oncology1792-362X2019-07-0191313610.2478/fco-2018-0005fco-2018-0005Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)Gouvas Nikolaos0Kalambaliki Telenia1Voutsina Alexandra2Saridaki Zenia3Tzardi Maria4Kalykaki Aristea5Sfakianaki Maria6Athanasiadis Athanasios7Xynos Evaghelos8Boukovinas Ioannis9Souglakos John10Colorectal department, Worcester Acute Hospitals NHS Trust, Worcester, UKLaboratory of translational cancer research, University of Crete, Heraklion, GreeceMedical Oncology Department, Asklepios Hospital, Heraklion, GreeceMedical Oncology Department, Asklepios Hospital, Heraklion, GreeceDepartment of Pathology, University of Crete, Heraklion, GreeceLaboratory of translational cancer research, University of Crete, Heraklion, GreeceLaboratory of translational cancer research, University of Crete, Heraklion, GreeceDepartment of Medical Oncology, General Hospital of Larissa, Larissa, GreeceColorectal department, InterClinic Hospital, Heraklion, GreeceDepartment of Medical Oncology, Bioclinic Hospital, Thessaloniki, GreeceLaboratory of translational cancer research, University of Crete, Heraklion, GreeceSeveral studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent prognostic factor for the response to treatment with anti-EGFR moAbs. The aim of this observational study was to assess the feasibility of the KRAS/NRAS mutational analysis in patients with metastatic colorectal cancer in Greece and to identify any correlations with known clinical characteristics and histopathologic features.https://doi.org/10.2478/fco-2018-0005kras-nras mutationcolorectal cancermetastatic disease
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Gouvas Nikolaos Kalambaliki Telenia Voutsina Alexandra Saridaki Zenia Tzardi Maria Kalykaki Aristea Sfakianaki Maria Athanasiadis Athanasios Xynos Evaghelos Boukovinas Ioannis Souglakos John
spellingShingle	Gouvas Nikolaos Kalambaliki Telenia Voutsina Alexandra Saridaki Zenia Tzardi Maria Kalykaki Aristea Sfakianaki Maria Athanasiadis Athanasios Xynos Evaghelos Boukovinas Ioannis Souglakos John Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG) Forum of Clinical Oncology kras-nras mutation colorectal cancer metastatic disease
author_facet	Gouvas Nikolaos Kalambaliki Telenia Voutsina Alexandra Saridaki Zenia Tzardi Maria Kalykaki Aristea Sfakianaki Maria Athanasiadis Athanasios Xynos Evaghelos Boukovinas Ioannis Souglakos John
author_sort	Gouvas Nikolaos
title	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
title_short	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
title_full	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
title_fullStr	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
title_full_unstemmed	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
title_sort	analysis of kras and nras mutations in greek patients with metastatic colorectal cancer (mcrc) on the registry of the gastro-intestinal cancer study group (gic-sg)
publisher	Sciendo
series	Forum of Clinical Oncology
issn	1792-362X
publishDate	2019-07-01
description	Several studies show that mutational profiles could influence treatment decisions in patients with metastatic CRC (mCRC). KRAS mutational status was the first step in biomarkers development in the era of molecular targeted therapies. Recently, NRAS mutational status was identified as an independent prognostic factor for the response to treatment with anti-EGFR moAbs. The aim of this observational study was to assess the feasibility of the KRAS/NRAS mutational analysis in patients with metastatic colorectal cancer in Greece and to identify any correlations with known clinical characteristics and histopathologic features.
topic	kras-nras mutation colorectal cancer metastatic disease
url	https://doi.org/10.2478/fco-2018-0005
work_keys_str_mv	AT gouvasnikolaos analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT kalambalikitelenia analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT voutsinaalexandra analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT saridakizenia analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT tzardimaria analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT kalykakiaristea analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT sfakianakimaria analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT athanasiadisathanasios analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT xynosevaghelos analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT boukovinasioannis analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg AT souglakosjohn analysisofkrasandnrasmutationsingreekpatientswithmetastaticcolorectalcancermcrcontheregistryofthegastrointestinalcancerstudygroupgicsg
_version_	1717782089570451456

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)

Similar Items